Field Notes #8: The Other Mushroom Boom
While psychedelic mushrooms fight for legal status, their boring cousins quietly became a near-$85 billion wellness industry. What the science on lion's mane and reishi actually shows — and where the marketing gets ahead of it.
This newsletter spends most of its time on the mushrooms that change your mind. There is another mushroom story running in parallel, quieter and far more commercial, and it is worth a look precisely because nobody is getting arrested over it.
Walk into any grocery store and the fungi have colonized the shelves. Lion's mane in the coffee. Reishi in the sleepy nighttime drink. Cordyceps in the pre-workout. Turkey tail in the capsule aisle next to the vitamin D. These are the "functional" mushrooms — non-psychedelic, sold on promises of sharper focus, calmer nerves, steadier immunity — and they have gone from health-store curiosity to mass-market default in about five years. One market analysis pegs the global functional mushroom category on a path toward roughly $85 billion by the mid-2030s. That is not a supplement trend. That is an industry.
The interesting tension is between the marketing and the evidence, because they are not in the same place. Some of these claims rest on real, if early, science. Lion's mane contains compounds that nudge nerve growth factor, and small human studies have hinted at modest cognitive and mood benefits. Reishi has a genuine research literature around immune signaling. Cordyceps shows up in fatigue and exercise studies with mixed but not empty results. There is something here.
What there mostly isn't yet is the large, repeated, human-scale proof that would justify the copy on the label. A lot of the strongest-sounding claims trace back to cell cultures, mice, or a single small trial that a marketing team then rounded up to certainty. The dose in your mushroom soda is often a fraction of what any study used, and independent testing has repeatedly found products that contain far less active material than the front of the package suggests. Some "mushroom" powders are mostly the grain the mushroom was grown on.
None of that makes the category a scam. It makes it early. The gap between "promising" and "proven" is exactly where wellness marketing likes to set up shop, and functional mushrooms are sitting right in the middle of it, selling a plausible story faster than the science can confirm or deny it.
There is a small irony worth sitting with. For a century we treated the mushrooms that get you high as dangerous and the ordinary ones as food. Now the ordinary ones are a multibillion-dollar wellness engine sold with barely a raised eyebrow, while their psychedelic cousins are still clawing their way toward legal medical use one trial at a time. Same kingdom, wildly different luck. If you are going to buy the reishi, buy it for what it plausibly is — a decent, mild, possibly helpful thing — and keep a little skepticism in the cart next to it.
— The Alkaloid
Field Notes is the mid-week dispatch from The Alkaloid. Forward this to someone who'd enjoy it. Subscribe at TheAlkaloid.com
Sources
- Precedence Research, "Functional Mushroom Market Size" — projection toward ~$84.78B by 2035 (2026)
- Mycroboost, "Top 5 Mushroom Supplement Trends to Watch in 2026"
- SporeBuddies, "Functional Mushroom Research Update 2025–2026: Lion's Mane, Cordyceps, Reishi & Turkey Tail"
